Bristol-Myers to Pay $11 Billion to License Cancer Drug
Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors. Bloomberg's Damian Garde reports. (Source: Bloomberg)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
24 minutes ago
- Wall Street Journal
Trump Administration Threatens to Pull Funding for California High-Speed Rail
The Trump administration threatened to yank billions in federal funding for California's high-speed rail project, saying the state had mismanaged it, causing delays and cost overruns. In a 310-page report, the Federal Railroad Administration found that the California High-Speed Rail Authority had defaulted on the terms of its agreements for two federal grants totaling over $4 billion. The agency gave the state 37 days to respond.
Bloomberg
25 minutes ago
- Bloomberg
Enterprise Products Says US Set to Deny Its China Ethane Export License
Enterprise Products Partners LP received a notice saying the US intends to deny licenses for three proposed cargoes of ethane heading to China as the Trump administration doubles down on security for exports to the country. The Houston-based midstream energy company has up to 20 days to issue a rebuttal to the notice from the Bureau of Industry and Security at the US Department of Commerce, Enterprise said in a statement Wednesday. The cargoes contain about 2.2 million barrels of ethane.
Bloomberg
35 minutes ago
- Bloomberg
Aluminum Executives Balk at Trump's Latest 50% Tariff Move
US President Donald Trump's newly imposed 50% tariff on aluminum imports may be too much for consumers to accept and crush demand, industry executives warned. 'We're concerned about the potential for demand destruction' from the levy especially at the present level, said Derek Prichett, senior vice president of global metals at Novelis Inc., at Harbor Aluminum's 17th summit in Chicago.
